Stribild (elvitegravir + cobicistat + emtricitabine (FTC) + tenofovir DF)
Stribild was approved in Europe in May 2013 and approved by NHS England for use in the UK in September 2013. It was approved in the USA in August 2012. Prior to approval it was called Quad.
Stribild is a 4-in-1 single combination pill that is taken once-daily, with food.
The active drugs in Stribild are:
- 150 mg elvitegravir (el-vye-TEG-rah-vir) – an integrase inhibitor.
- 150 mg cobicistat (cob-BIS-is-stat) – a “booster” for elvitegravir.
- 300 mg tenofovir. (245 mg as tenofovir fumerate)
- 200 mg FTC.
In a recent update to the US DHHS guidelines Stribild is now included as a preferred first combination.
- Stribild needs to be taken with food. The amount of type of food is not included in this recommendation but it may be important to include fat. The food interaction study reported that elvitegravir exposure (total drug levels over the dose period, called the AUC) increased by 36% with a light meal (~373 kcal, 20% fat) and by 91% with a high-fat meal (~800 kcal, 50% fat).
- Drug interactions include with antacid medicines which can reduce levels of elvitegravir. Antacids need to be be separated by at least four hours.
- A potential interaction means that multivitamins and elvitegravir need to be separated by at least four hours.
- Stribild should not be used in people with reduced kidney function defined as having eGRF levels less than 70 mL/minute.
The European patient leaflet and detailed Product Information for Stribild are available in PDF format from this link at the European Medicines Agency (EMA) website.
The Patient Information is a simplified summary: what the drug is, why it is used, results from studies and cautions including side effects.
The Product Information is a detailed technical summary that you can access as a PDF file by clicking the ‘Product Information’ tab. It describes more precisely how the drug works and how it is processed by your body. This includes, for example, reported food interaction studies in terms of calories or fat content. It includes more details of the study results and a full list of side effects and drug interactions.
Link to EU prescribing information. (html pages)
Link to US prescribing information. (PDF document)